Skip to main content

Table 1 Clinical and biochemical characteristics of the patients with STEMI stratified by the presence of hyperuricemia

From: Hyperuricemia is associated with an increased prevalence of ventricular tachycardia and fibrillation in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention

Characteristics

Patients with hyperuricemia

Patients without hyperuricemia

p value

(n = 147)

(n = 487)

Serum uric acid 8.9 (7.1–8.9) mg/dl

Serum uric acid 5.0 (4.1–5.7) mg/dl

Demographic characteristics

Age (year)

65.6 ± 15.1

62.0 ± 13.1

0.003

Male

114 (77.6)

389 (79.9)

0.542

Hypertension

97 (66.0)

265 (54.4)

0.013

Diabetes mellitus

27 (18.4)

87 (17.9)

0.889

Dyslipidemia

4 (2.7)

12 (2.5)

0.772

Current smoking

71 (48.3)

278 (57.1)

0.061

Previous myocardial infarction

6 (4.1)

11 (2.3)

0.246

Previous revascularization

5 (3.4)

19 (3.9)

0.781

Previous stroke

15 (10.2)

27 (5.5)

0.046

Clinical presentation

SVT/VF before PPCI

8 (5.4)

19 (3.9)

0.417

Cardiogenic shock at admission

42 (28.6)

69 (14.2)

0.000

hsCRP (mg/L)

8.0 (3.6–19.8)

5.0 (2.0–16.0)

0.002

Serum potassium (mmol/L)

4.0 ± 0.4

4.0 ± 0.5

0.220

Serum natrium (mmol/L)

139.5 ± 4.1

138.6 ± 3.3

0.016

Serum chlorinum (mmol/L)

105.5 ± 7.7

105.1 ± 4.00

0.452

eGFRMDRD (ml/min/1.73m2)

57.1 ± 20.2

80.2 ± 22.2

0.000

Fasting glucose (mmol/L)

8.2 ± 3.5

7.1 ± 2.8

0.001

HbA1c (%)

6.4 ± 1.5

2.7 ± 1.7

0.540

Peak troponin I (ng/ml)

67.6 (22.8–153.2)

42.8 (17.9–87.0)

0.009

BNP (pg/ml)

1149.5 (302.0–3376.5)

709.5 (254.3–1698.8)

0.003

Triglycerides (mmol/L)

1.7 ± 1.2

1.5 ± 1.1

0.056

Total cholesterol (mmol/L)

4.3 ± 1.3

4.2 ± 1.1

0.336

HDL-C (mmol/L)

1.0 ± 0.3

1.0 ± 0.3

0.133

LDL-C (mmol/L)

2.9 ± 1.0

2.8 ± 0.8

0.628

LVEF (%)

57.5 ± 11.4

60.1 ± 9.1

0.018

Medical treatment after PPCI

Aspirin

146 (99.3)

486 (99.8)

0.410

Clopidogrel

135 (91.8)

462 (94.9)

0.170

Ticagrelor

11 (7.5)

25 (5.1)

0.281

Beta-blockers

91 (61.9)

328 (67.4)

0.222

Statin

138 (93.9)

485 (99.6)

0.000

ACEI/ARB

98 (66.7)

333 (68.4)

0.697

Aminodarone

21 (14.3)

48 (9.9)

0.131

Lidocaine

14 (9.5)

28 (5.7)

0.107

  1. Sample size, n = 634. Data are expressed as mean ± OR, number of patients (percentage) or median (range)
  2. STEMI, ST-segment elevation myocardial infarction; SVT, sustained ventricular tachycardia; VF, ventricular fibrillation; LVEF, left ventricular ejection fraction; PPCI, primary percutaneous coronary intervention; hsCRP, hypersensitive C reactive protein; eGFR, estimated glomerular filtration rate; BNP, B-type natriuretic peptides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker